ReviewBioMed research international2018
Eosinophils from Physiology to Disease: A Comprehensive Review.
Review in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 160 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
160 citing papers in PubMed, 1 synthesis or guideline pooled it, 305 citations in OpenAlex.
- The role of anti-eosinophilic therapies in eosinophilic granulomatosis with polyangiitis: a systematic review.Rheumatology international · 2023Pooled it
- Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Effect of atorvastatin on serum periostin and blood eosinophils in asthma - a placebo-controlled randomized clinical trial.The Journal of international medical research · 2021Trial
- Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma.Pediatric pulmonology · 2019Trial
- Δ9-Tetrahydrocannabinol exposure shifts eosinophil and macrophage transcriptional programs toward an anti-inflammatory phenotype in helminth infection.Journal of leukocyte biology · 2026Article
- Peripheral Hematological and Immune-Endocrine Markers in Children with Specific Learning Disorder: An Exploratory Retrospective Case-Control Study.Brain sciences · 2026Article
- Beyond conventional mechanisms of prosthetic valve thrombosis: immune, genetic, hematologic, hormonal, and hemodynamic perspectives.Journal of thrombosis and thrombolysis · 2026Review
- Redefining Hematology Referral Thresholds for Eosinophilia.European journal of haematology · 2026Review
- Non-atherosclerotic myocardial infarction in hypereosinophilic syndrome: emerging insights and therapeutic approaches.Heart (British Cardiac Society) · 2026Review
- Mast cells support lung eosinophil homeostasis and the acute innate immune response to respiratory syncytial virus.Nature communications · 2026Article
- Risk factors for recurrence following surgical treatment of pediatric hepatic hydatid disease.Pediatric surgery international · 2026Observational
- Linking Mitochondrial Dysfunction to the Immune Microenvironment in HFpEF: An Integrated Bioinformatics and Experimental Approach.Immunity, inflammation and disease · 2026Article
- Reframing Eczema: Th2-Skewed Contact Sensitization, Atopy Patch Testing, and Systemic Contact Dermatitis.Current allergy and asthma reports · 2026Review
- Eosinophils in solid cancers: sentinels, predictors, and therapeutic allies.Journal of experimental & clinical cancer research : CR · 2026Review
- From neuroimmune circuits to targeted therapy of chronic pruritus.Pharmacological reviews · 2026Review
- Catastrophic antiphospholipid syndrome with eosinophilia mimicking hypereosinophilic syndromes with disseminated intravascular coagulation: a case report.Journal of medical case reports · 2026Article
- Drug-induced eosinophilic pneumonia: a real-world data mining study of the FAERS and Vigibase database reveals potential safety signals and risk patterns.Frontiers in medicine · 2026Article
- Eosinophilic Organ Complications Associated with Dupilumab Therapy - Narrative Review and Current Evidence.Journal of asthma and allergy · 2026Article
- The Immune Architecture of Eosinophilic Esophagitis: Mechanisms, Therapeutic Targets, and Precision Management.ImmunoTargets and therapy · 2026Review
- Associated diagnostic spectrum and stratified characteristics of patients with eosinophilia: a retrospective study.Frontiers in medicine · 2026Article
100 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite being the second least represented granulocyte subpopulation in the circulating blood, eosinophils are receiving a growing interest from the scientific community, due to their complex pathophysiological role in a broad range of local and systemic inflammatory diseases as well as in cancer and thrombosis. Eosinophils are crucial for the control of parasitic infections, but increasing evidence suggests that they are also involved in vital defensive tasks against bacterial and viral pathogens including HIV. On the other side of the coin, eosinophil potential to provide a strong defensive response against invading microbes through the release of a large array of compounds can prove toxic to the host tissues and dysregulate haemostasis. Increasing knowledge of eosinophil biological behaviour is leading to major changes in established paradigms for the classification and diagnosis of several allergic and autoimmune diseases and has paved the way to a "golden age" of eosinophil-targeted agents. In this review, we provide a comprehensive update on the pathophysiological role of eosinophils in host defence, inflammation, and cancer and discuss potential clinical implications in light of recent therapeutic advances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.